Aquestive Therapeutics (AQST) Cost of Revenue (2017 - 2026)

Aquestive Therapeutics' Cost of Revenue history runs 10 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 5.01% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $23.7 million (up 69.4% YoY), while the FY2025 annual figure was $18.6 million, up 3.82% from the prior year.
• Cost of Revenue was $3.5 million for Q1 2026 at Aquestive Therapeutics, down from $14.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $14.3 million in Q4 2025 to a low of -$14.1 million in Q4 2022.
• Historically, Cost of Revenue has averaged $3.6 million across 5 years, with a median of $4.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue plunged 518.33% in 2022, then surged 215.29% in 2025.
• A 5-year view of Cost of Revenue shows it stood at -$14.1 million in 2022, then jumped by 138.93% to $5.5 million in 2023, then declined by 17.55% to $4.5 million in 2024, then soared by 215.29% to $14.3 million in 2025, then plunged by 75.66% to $3.5 million in 2026.
• The last three Cost of Revenue figures came in at $3.5 million (Q1 2026), $14.3 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.